Biotech Exit: Million Arcellx Sparks Investor Reassessment
A notable stake sale in Arcellx turned heads in biotech investing. This article unpack the $26 million exit, why the ...
Assess whether Risk Parity or index funds better suit your retirement plan by examining diversification, cost, and potential risk/return trade-offs.
27,926 articlesA notable stake sale in Arcellx turned heads in biotech investing. This article unpack the $26 million exit, why the ...
When a tech giant faces a costly lawsuit over a celebrity image, it isn’t just a legal story—it’s a personal finance ...
A notable fund pulled out of a multi-million dollar DNOW position last quarter, triggering questions about strategy a...
As 2026 unfolds, investors face a pivotal choice between Lyft and Uber Technologies. This article breaks down strateg...
When yields rise, even patient investors can feel the pressure. This guide explains what rising treasury yields spook...
Market rallies can mask drift in your asset mix. Learn why right now is a great moment to rebalance and how to do it ...
Germany plans sweeping changes to its pension system in 2026. This article breaks down what the reforms could mean fo...
A growing share of households are adopting financial minimalism as markets stay volatile in 2026. The approach favors...
A new generation rewrites the wealth playbook, stacking income streams and investing smarter as traditional paths gro...
As teens head into summer jobs, experts say disciplined saving and smart investing can transform a paycheck into deca...
Growth-focused SPYG has outpaced SPYV over the last decade, a trend supported by AI spending and mega-cap tech. The g...
Bank on a nuclear surge in 2026? URNM and URA offer different routes to exposure. This piece breaks down urnm: which ...